---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-000193"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2024-01-03T23:59:59+00:00"
generated_at: "2026-06-07T04:59:56.980916+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Enveric corrects EB-003 binding affinity data, shows 1000x greater potency than previously reported

## Summary
- EB-003 exhibits 5-HT2A partial agonism with Ki of 0.2 µM (corrected from 0.2 mM) – 1000x higher binding affinity.
- EB-003 binds 5-HT1A receptor with Ki of 3.3 µM (corrected from 3.3 mM).
- Enveric to initiate preclinical IND-enabling activities in early 2024 for EB-003.
- EB-003 selected as lead candidate from EVM301 Series; designed to promote neuroplasticity without hallucinations.
- Company used PsyAI platform to screen 51 analogs; EB-003 showed no significant head-twitch response in mice.

## SEC filing metadata
- accession: 0001493152-24-000193
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2024-01-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315224000193/0001493152-24-000193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315224000193/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-000193
- JSON: https://secwatch.observer/filing/0001493152-24-000193.json
- Plain text: https://secwatch.observer/filing/0001493152-24-000193.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.